Figure 3 | Scientific Reports

Figure 3

From: A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3)

Figure 3

Salirasib and Candesartan are non-toxic PRL inhibitors. HEK293T cells were cultured with drugs at a range of concentrations and viability was assessed after 16 h. Drugs were sub-divided into those that were (a) minimally toxic, (b) caused increased viability, and (c) were highly toxic. Viability was measured as cellular reduction potential using MTT dye, and normalized to 1% DMSO control. Assays were run in triplicate in three independent experiments. Data represent mean viability and error bars represent standard deviation between assays.

Back to article page